Cancer Communications | Targeting TREM2+ and TIMD4+ Macrophages Reprograms the Tumor Microenvironment and Enhances PD-1 Blockade Efficacy in Cholangiocarcinoma

This study reveals the critical role of macrophage subsets in immune evasion in cholangiocarcinoma, providing direct experimental evidence for designing tumor microenvironment remodeling strategies combined with immune checkpoint blockade.

 

Literature Overview

This article, titled "Targeting TREM2+ and TIMD4+ Macrophages Reprograms the Tumor Microenvironment and Enhances PD-1 Blockade Efficacy in Intrahepatic Cholangiocarcinoma," published in Cancer Communications, systematically explores the spatial heterogeneity of macrophages in intrahepatic cholangiocarcinoma (ICC) and their regulatory mechanisms on immunotherapy.

Background Knowledge

Intrahepatic cholangiocarcinoma (cholangiocarcinoma) is a malignant tumor with a poor prognosis. Although immunotherapies such as PD-1 inhibitors have achieved breakthroughs in some solid tumors, the response rate in cholangiocarcinoma remains low, suggesting the existence of incompletely elucidated immunosuppressive mechanisms within the tumor microenvironment (TME). As a core component of the TME, the functional heterogeneity of macrophages directly affects the cytotoxic function of CD8+ T cells. Currently, there is a lack of systematic research on the specific spatial distribution, interaction networks, and tumorigenic mechanisms of TREM2 and TIMD4, two inhibitory receptors highly expressed in myeloid cells, in cholangiocarcinoma. In particular, how macrophages in the tumor margin construct a physical immune barrier and how they promote tumor invasion via the uPA-uPAR axis remain urgent mechanistic challenges. This study addresses this gap to clarify the specific roles of TREM2+ and TIMD4+ macrophages in immune evasion in cholangiocarcinoma.

 

 

Research Methods and Core Experiments

The authors employed a multi-omics integrated analysis strategy. First, tumor tissues, para-tumor tissues, and tumor margin tissues from 16 patients were collected. Single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics were utilized to map the cellular atlas of the cholangiocarcinoma microenvironment. To validate findings from human samples, the research team constructed Trem2-/- knockout mouse models and combined them with Kras-P19 and Yap-Akt induced cholangiocarcinoma mouse models for in vivo efficacy evaluation. Key evidence chains include: Flow cytometry and multiplex immunofluorescence (mIF) confirmed the high abundance and aggregation of TREM2+ macrophages at the tumor margin; in vitro co-culture systems demonstrated that TREM2+ macrophages induce CD8+ T cell exhaustion and promote the generation of regulatory T cells (Tregs); Transwell and scratch assays revealed that TREM2+ macrophages promote tumor cell invasion and the transformation of stellate cells into myofibroblasts via the uPA-uPAR axis.

Key Conclusions and Perspectives

• TREM2+ macrophages within the tumor core construct a potent immunosuppressive microenvironment by exhausting CD8+ T cells and inducing Treg generation.
• In the tumor margin, TREM2+ macrophages promote tumor invasion via the uPA-uPAR axis and induce the transformation of hepatic stellate cells into myofibroblasts, forming a physical barrier that hinders CD8+ T cell infiltration.
• TIMD4+ macrophages in adjacent tissues also suppress CD8+ T cell function, serving as another critical factor in immune evasion.
• Combined treatment with anti-TREM2, anti-TIMD4, and anti-PD-1 antibodies significantly enhanced therapeutic efficacy and prolonged survival in cholangiocarcinoma mouse models, proving that targeting these two macrophage subsets is an effective strategy to overcome immunotherapy resistance.

Research Significance and Prospects

This discovery provides new combination therapy targets for drug development in cholangiocarcinoma, suggesting that single-agent PD-1 blockade may be insufficient to reverse immunosuppression mediated by specific macrophage subsets. In terms of clinical monitoring, the expression levels of TREM2 and TIMD4 may serve as biomarkers for predicting immunotherapy response. Furthermore, the cholangiocarcinoma mouse models and spatial transcriptomics analysis workflow established in this study provide a standard reference for disease modeling in future research on the spatiotemporal dynamics of the tumor microenvironment.

 

 

Conclusion

This study deeply analyzes the heterogeneity of macrophages in cholangiocarcinoma, particularly the core role of TREM2+ and TIMD4+ subsets in constructing an immunosuppressive microenvironment. By revealing the dual mechanisms of TREM2+ macrophages forming physical barriers at the tumor margin and inducing CD8+ T cell exhaustion, the study not only explains why some patients do not respond to PD-1 therapy but also provides a solid theoretical foundation for developing combination targeting strategies. From laboratory discovery to clinical translation, targeting TREM2 and TIMD4 is expected to become a key breakthrough in breaking the impasse of immunotherapy in cholangiocarcinoma, significantly improving patient survival benefits, and laying the cornerstone for building a more precise comprehensive care system for cholangiocarcinoma.

 

Yao Li, Hongwen Liu, Lei Xu, Feng Shen, and Kui Wang. Targeting TREM2+ and TIMD4+ Macrophages Reprograms the Tumor Microenvironment and Enhances PD-1 Blockade Efficacy in Intrahepatic Cholangiocarcinoma. Cancer Communications.